A functional toll-like receptor 8 variant is associated with HIV disease restriction

Journal of Infectious Diseases

Volumn 198, Issue 5, 2008, Pages 701-709

  Oh, D Y ^a   Taube, S ^a,b,e   Hamouda, O ^b   Kucherer C ^b   Poggensee, G ^b   Jessen, H ^c   Eckert, J K ^a   Neumann, K ^a   Storek, A ^a   Pouliot, M ^d   Borgeat, P ^d   Oh, N ^a,c   Schreier, E ^b   Pruss, A ^a   Hattermann, K ^d   Schumann, Ralf R ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ROBERT KOCH INSTITUTE   (Germany)

^c Praxisgemeinschaft Jessen   (Germany)

^d Université Laval   (Canada)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TOLL LIKE RECEPTOR 8;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; FEMALE; GENE FUNCTION; GENE LOCATION; GENE OVEREXPRESSION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOGENESIS; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NEUTROPHIL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; X CHROMOSOME;

ADULT; CELL LINE; DISEASE PROGRESSION; EXONS; FEMALE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NF-KAPPA B; POLYMORPHISM, SINGLE NUCLEOTIDE; TOLL-LIKE RECEPTOR 8;

EID: 50949083798     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/590431     Document Type: Article

References (43)

1. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20:197-216.
2. Beutler B, Jiang Z, Georgel P, et al. Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large. Annu Rev Immunol 2006; 24:353-89.
3. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004; 303:1529-31.
4. Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004; 303:1526-9.
5. Beignon AS, McKenna K, Skoberne M, et al. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest 2005; 115:3265-75.
6. Wille-Reece U, Flynn BJ, Lore K, et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med 2006; 203:1249-58.
7. Schlaepfer E, Audige A, Joller H, Speck RF. TLR7/8 triggering exerts opposing effects in acute versus latent HIV infection. J Immunol 2006; 176:2888-95.
8. Meier A, Alter G, Frahm N, et al. MyD88-dependent immune activation mediated by HIV-1-encoded TLR ligands. J Virol 2007; 81:8180-91.
9. Alter G, Suscovich TJ, Teigen N, et al. Single-stranded RNA derived from HIV-1 serves as a potent activator of NK cells. J Immunol 2007; 178:7658-66.
10. Schröder NWJ, Schumann RR. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis 2005; 5:156-64.
11. Mockenhaupt FP, Cramer JP, Hamann L, et al. Toll-like receptor (TLR) polymorphisms in African children: Common TLR-4 variants predispose to severe malaria. Proc Natl Acad Sci USA 2006; 103:177-82.
12. Khor CC, Chapman SJ, Vannberg FO, et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet 2007; 39:523-8.
13. Bochud PY, Hersberger M, Taffe P, et al. Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection. AIDS 2007; 21:441-6.
14. Schott E, Witt H, Neumann K, et al. A Toll-like receptor 7 single nucleotide polymorphism protects from advanced inflammation and fibrosis in male patients with chronic HCV-infection. J Hepatol 2007; 47:203-11.
15. Neifer S, Somogyi S, Schlote F, Berg T, Poggensee G, Kuecherer C. Persistence of a sexually transmitted highly resistant HIV-1: pol quasispecies evolution over 33 months in the absence of treatment. AIDS 2006; 20:2231-3.
16. Speelmon EC, Livingston-Rosanoff D, Li SS, et al. Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection. J Virol 2006; 80:2463-71.
17. Chuang TH, Ulevitch RJ. Cloning and characterization of a sub-family of human toll-like receptors: hTLR7, hTLR8 and hTLR9. Eur Cytokine Netw 2000; 11:372-8.
18. Du X, Poltorak A, Wei Y, Beutler B. Three novel mammalian toll-like receptors: gene structure, expression, and evolution. Eur Cytokine Netw 2000; 11:362-71.
19. Hornung V, Rothenfusser S, Britsch S, et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002; 168:4531-7.
20. Hattermann K, Picard S, Borgeat M, Leclerc P, Pouliot M, Borgeat P. The Toll-like receptor 7/8-ligand resiquimod (R-848) primes human neutrophils for leukotriene B4, prostaglandin E2 and platelet-activating factor biosynthesis. FASEB J 2007; 21:1575-85.
21. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273:1856-62.
22. Winkler C, Modi W, Smith MW, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort. Science 1998; 279:389-93.
23. Trachtenberg E, Korber B, Sollars C, et al. Advantage of rare HLA supertype in HIV disease progression. Nat Med 2003; 9:928-35.
24. Martin MP, Qi Y, Gao X, et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007; 39:733-40.
25. Ferwerda B, McCall MB, Alonso S, et al. TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proc Natl Acad Sci USA 2007; 104:16645-50.
26. Molina JM, Scadden DT, Byrn R, Dinarello CA, Groopman JE. Production of tumor necrosis factor alpha and interleukin 1 beta by monocytic cells infected with human immunodeficiency virus. J Clin Invest 1989; 84:733-7.
27. Lokensgard JR, Gekker G, Ehrlich LC, Hu S, Chao CC, Peterson PK. Proinflammatory cytokines inhibit HIV-1 (SF162) expression in acutely infected human brain cell cultures. J Immunol 1997; 158:2449-55.
28. Lane BR, Markovitz DM, Woodford NL, Rochford R, Strieter RM, Coffey MJ. TNF-alpha inhibits HIV-1 replication in peripheral blood monocytes and alveolar macrophages by inducing the production of RANTES and decreasing C-C chemokine receptor 5 (CCR5) expression. J Immunol 1999; 163:3653-61.
29. Fortis C, Biswas P, Soldini L, et al. Dual role of TNF-alpha in NK/LAK cell-mediated lysis of chronically HIV-infected U1 cells: concomitant enhancement of HIV expression and sensitization of cell-mediated lysis. Eur J Immunol 1999; 29:3654-62.
30. Ancuta P, Bakri Y, Chomont N, Hocini H, Gabuzda D, Haeffner-Cavaillon N. Opposite effects of IL-10 on the ability of dendritic cells and macrophages to replicate primary CXCR4-dependent HIV-1 strains. J Immunol 2001; 166:4244-53.
31. Pott GB, Sailer CA, Porat R, et al. Effect of a four-week course of interleukin-10 on cytokine production in a placebo-controlled study of HIV-1-infected subjects. Eur Cytokine Netw 2007; 18:49-58.
32. Clerici M, Shearer GM. A TH1→TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993; 14:107-11.
33. Sozzani S, Ghezzi S, Iannolo G, et al. Interleukin 10 increases CCR5 expression and HIV infection in human monocytes. J Exp Med 1998; 187:439-44.
34. Finnegan A, Roebuck KA, Nakai BE, et al. IL-10 cooperates with TNF-alpha to activate HIV-1 from latently and acutely infected cells of monocyte/macrophage lineage. J Immunol 1996; 156:841-51.
35. Coffey MJ, Phare SM, George S, Peters-Golden M, Kazanjian PH. Granulocyte colony-stimulating factor administration to HIV-infected subjects augments reduced leukotriene synthesis and anticryptococcal activity in neutrophils. J Clin Invest 1998; 102:663-70.
36. Thivierge M, Le Gouill C, Tremblay MJ, Stankova J, Rola-Pleszczynski M. Prostaglandin E2 induces resistance to human immunodeficiency virus-1 infection in monocyte-derived macrophages: downregulation of CCR5 expression by cyclic adenosine monophosphate. Blood 1998; 92:40-5.
37. Flamand L, Borgeat P, Lalonde R, Gosselin J. Release of anti-HIV mediators after administration of leukotriene B4 to humans. J Infect Dis 2004; 189:2001-9.
38. Kozak M. Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell 1986; 44:283-92.
39. Kozak M. At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J Mol Biol 1987; 196:947-50.
40. Kozak M. An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res 1987; 15:8125-48.
41. Choo KH, Tan TW, Ranganathan S. SPdb - a signal peptide database. BMC Bioinformatics 2005; 6:249.
42. Kang YJ, Wingerd BA, Arakawa T, Smith WL. Cyclooxygenase-2 gene transcription in a macrophage model of inflammation. J Immunol 2006; 177:8111-22.
43. Vila-del Sol V, Fresno M. Involvement of TNF and NF-kappa B in the transcriptional control of cyclooxygenase-2 expression by IFN-gamma in macrophages. J Immunol 2005; 174:2825-33.